Download

For professionals

One measurement says little about a brain. A series says a great deal.

Remind builds a longitudinal picture of brain health in the phase before any diagnosis. A filter at the front of the pathway rather than another door into it.

Arrange a conversation Send us a message
  1. Speech
  2. Memory
  3. Typing
  4. Functioning
  5. Lifestyle
Schematic. Each dot is a reading someone takes at home, each measurement on its own rhythm. The value is in the shape they make.

The problem

The phase before diagnosis belongs to no one

Dementia care is organised around the diagnosis and everything that follows it. Someone who notices a change and has no diagnosis has one place to go, which is a clinician. That is exactly where the shortage bites.

A large share of those people have no neurodegenerative condition. They are looking for clarity, and at the moment the consulting room is the only place to find it.

  • 1 in 3

    Around a third of patients at specialist memory clinics have a functional cognitive disorder: real symptoms, no neurodegenerative cause.

    Remind wants to reduce that misdirected inflow at the GP and the memory clinic.

  • 45%

    The Lancet Commission estimates that around 45% of dementia cases could be prevented or delayed by addressing fourteen modifiable risk factors.

    Every year of delay saves care costs and keeps the pathway manageable.

  • 2.6 → 1.7

    In the Netherlands the ratio of informal carers per person with dementia falls from 2.6 in 2024 to 1.7 in 2040, while the number of people with dementia heads towards 610,000 by 2050.

    The scarcer informal care becomes, the earlier you want to know who needs attention.

Sources: Cabreira et al., Clinical signs in functional cognitive disorders, Journal of Psychosomatic Research (2023) Lancet Commission, Dementia prevention, intervention and care (2024) Dutch National Dementia Strategy 2026-2030

A woman in middle age at her kitchen table, looking at her phone with a cup of tea beside her.

The demand

People want to know, and misjudge themselves

Researchers at Erasmus MC in Rotterdam asked 687 adults whether they would want to know their risk of dementia over the coming ten years. Two thirds did. Had a medicine been available, that rose to more than four in five.

The same group put their own risk at around twenty per cent, where for most adults it is a few per cent at most.

The demand for clarity is already there, and what people believe about themselves is often wrong.

A clear majority of adults want to know their dementia risk, on research from Erasmus MC (DOQ, in Dutch)

Working together

Who we are building for

Four kinds of partner, with different questions.

  • Health insurers

    • An offer for the phase where there is no diagnosis and no reason for a referral.
    • Fits within existing prevention budgets in supplementary policies, alongside the lifestyle checks already in them.
    • Aligns with the Dutch national dementia pathway agreements, aimed at limiting the inflow into insured care.

  • Care providers and dementia networks

    • The Dutch National Dementia Strategy asks for case management from the earliest suspicion onwards. In practice that rarely starts early.
    • A picture over time helps with triage: who needs attention now, and who can be followed.
    • People arrive prepared, with months of history rather than a single moment.

  • Research

    • Longitudinal measurement in a community-dwelling population without a diagnosis.
    • Measurement between study visits, with less burden per participant.
    • Recruitment and pre-selection for cohort and intervention studies. We work with researchers at Amsterdam UMC and Maastricht University.

  • Pharma and life sciences

    • Cohort identification for early-phase trials, where screen failure is a major cost.
    • Real-world data on the course before diagnosis, with functional outcome measures.
    • Monitoring in practice, usable for the evidence questions around reimbursement.

Our hypothesis

Reassurance where it fits, direction where it is needed

We think that following people in a structured way over time lowers demand on the GP and on the memory clinic. That is the claim we are building the evidence for, together with partners.

  • Reassure

    Most people who come forward have no disease. A picture over time gives them clarity without an appointment.

  • Follow

    If nothing changes, we keep measuring. That is a result in itself, and one nobody records today.

  • Refer

    If something does change, the person walks into that conversation prepared and with a reason.

What it rests on

Measurements grounded in research

The Remind app is a wellness product. We do not diagnose, and we do not show the raw analyses or scores to the person using it. What sits underneath is a different matter: the same validated instruments a doctor or neurologist works with.

Those instruments are not all equally far along. Below is where each measurement stands, with the publication to check it against.

The clinical relevance of a combined longitudinal profile is what we are working on with academic partners. That is the blank spot in this field, and the reason we are looking for research rather than a certificate.

Data

How we handle data

People trust us with sensitive data at a time when they are worried. That calls for restraint, towards partners as much as anyone.

  • Consent per purpose

    Taking part in research or a partner programme needs its own consent. Using the app never depends on it.

  • Pseudonymised where it can be

    For research and analysis we work with pseudonymised data. Partners receive no identifiable personal data.

  • No trade in personal data

    Our value is in aggregated insight and in collaboration. We do not sell personal data.

  • Access and deletion

    People can see their data and have it deleted, as the GDPR requires.

Read the privacy statement